Inefficient boosting of antitumor CD8+ T cells by dendritic-cell vaccines is rescued by restricting T-cell cytotoxic function

OncoImmunology

Volumn 1, Issue 9, 2012, Pages 1507-1516

  Ma, Joel Zhi Iong ^a,b,d   Yang, Jianping ^a   Qin, Jim S ^a,e   Richter, Antonia ^a,f   Perret, Rachel ^a,g   El Deiry, Wafik S ^c   Finnberg, Niklas ^c   Ronchese, Franca ^a,b  

^a MALAGHAN INSTITUTE OF MEDICAL RESEARCH   (New Zealand)

^b VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^c PENN STATE CANCER INSTITUTE   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e CENTENARY INSTITUTE   (Australia)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Cytotoxicity; Dendritic cells; Perforin; Rodent; T cells; Tumor immunotherapy

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; PERFORIN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; LEWIS CARCINOMA; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 84879189567     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.22128     Document Type: Article

References (50)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52; PMID:9521319; http://dx.doi.org/10.1038/32588.
2. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258.
3. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science.1203486.
4. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P. Human T cell responses against melanoma. Annu Rev Immunol 2006; 24:175-208; PMID:16551247; http://dx.doi.org/10.1146/annurev.immunol.24.021605.090733.
5. Romero P, Dunbar PR, Valmori D, Pittet M, Ogg GS, Rimoldi D, et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J Exp Med 1998; 188:1641-50; PMID:9802976; http://dx.doi.org/10.1084/jem.188.9.1641.
6. Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999; 5:677-85; PMID:10371507; http://dx.doi.org/10.1038/9525.
7. Demotte N, Stroobant V, Courtoy PJ, Van Der Smissen P, Colau D, Luescher IF, et al. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 2008; 28:414-24; PMID:18342010; http://dx.doi.org/10.1016/j.immuni.2008.01.011.
8. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 2009; 114:1537-44; PMID:19423728; http://dx.doi.org/10.1182/blood-2008-12-195792.
9. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res 2007; 13:1757-61; PMID:17363529; http://dx.doi.org/10.1158/1078-0432.CCR-06-2599.
10. Ulchaker J, Panuto J, Rayman P, Novick A, Elson P, Tubbs R, et al. Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12. J Immunother 1999; 22:71-9; PMID:9924702; http://dx.doi.org/10.1097/00002371-199901000-00010.
11. Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Liénard D, Lejeune F, et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res 2004; 64:2865-73; PMID:15087405; http://dx.doi.org/10.1158/0008-5472.CAN-03-3066.
12. Mahnke YD, Devevre E, Baumgaertner P, Matter M, Rufer N, Romero P, et al. Human melanomaspecific CD8(+) T-cells from metastases are capable of antigen-specific degranulation and cytolysis directly ex vivo. Oncoimmunology 2012; 1:467- 530; PMID:22754765; http://dx.doi.org/10.4161/onci.19856.
13. Finn OJ. Cancer immunology. N Engl J Med 2008; 358:2704-15; PMID:18565863; http://dx.doi.org/10.1056/NEJMra072739.
14. Hermans IF, Ritchie DS, Yang J, Roberts JM, Ronchese F. CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of antitumor immunity. J Immunol 2000; 164:3095-101; PMID:10706699.
15. Loyer V, Fontaine P, Pion S, Hétu F, Roy DC, Perreault C. The in vivo fate of APCs displaying minor H antigen and/or MHC differences is regulated by CTLs specific for immunodominant class I-associated epitopes. J Immunol 1999; 163:6462-7; PMID:10586037.
16. Opferman JT, Ober BT, Narayanan R, Ashton-Rickardt PG. Suicide induced by cytolytic activity controls the differentiation of memory CD8(+) T lymphocytes. Int Immunol 2001; 13:411-9; PMID:11282980; http://dx.doi.org/10.1093/intimm/13.4.411.
17. Kemp RA, Ronchese F. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity. J Immunol 2001; 167:6497-502; PMID:11714817.
18. Yang J, Huck SP, McHugh RS, Hermans IF, Ronchese F. Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo. Proc Natl Acad Sci U S A 2006; 103:147- 52; PMID:16373503; http://dx.doi.org/10.1073/pnas.0509054103.
19. Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN. Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 1997; 6:715-26; PMID:9208844; http://dx.doi.org/10.1016/S1074-7613(00)80447-1.
20. Ma JZ, Lim SN, Qin JS, Yang J, Enomoto N, Ruedl C, et al. Murine CD4+ T cell responses are inhibited by cytotoxic T cell-mediated killing of dendritic cells and are restored by antigen transfer. PLoS One 2012; 7:e37481; PMID:22649530; http://dx.doi.org/10.1371/journal.pone.0037481.
21. Veiga-Fernandes H, Walter U, Bourgeois C, McLean A, Rocha B. Response of naïve and memory CD8+ T cells to antigen stimulation in vivo. Nat Immunol 2000; 1:47-53; PMID:10881174; http://dx.doi.org/10.1038/76907.
22. Matloubian M, Suresh M, Glass A, Galvan M, Chow K, Whitmire JK, et al. A role for perforin in downregulating T-cell responses during chronic viral infection. J Virol 1999; 73:2527-36; PMID:9971838.
23. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, Bhawan S, Certain S, Mathew PA, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286:1957-9; PMID:10583959; http://dx.doi.org/10.1126/science.286.5446.1957.
24. Badovinac VP, Tvinnereim AR, Harty JT. Regulation of antigen-specific CD8+ T cell homeostasis by perforin and interferon-gamma. Science 2000; 290:1354-8; PMID:11082062; http://dx.doi.org/10.1126/science.290.5495.1354.
25. Badovinac VP, Hamilton SE, Harty JT. Viral infection results in massive CD8+ T cell expansion and mortality in vaccinated perforin-deficient mice. Immunity 2003; 18:463-74; PMID:12705850; http://dx.doi.org/10.1016/S1074-7613(03)00079-7.
26. Jordan MB, Hildeman D, Kappler J, Marrack P. An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 2004; 104:735-43; PMID:15069016; http://dx.doi.org/10.1182/blood-2003-10-3413.
27. Belz GT, Zhang L, Lay MD, Kupresanin F, Davenport MP. Killer T cells regulate antigen presentation for early expansion of memory, but not naive, CD8+ T cell. Proc Natl Acad Sci U S A 2007; 104:6341- 6; PMID:17400753; http://dx.doi.org/10.1073/pnas.0609990104.
28. Lykens JE, Terrell CE, Zoller EE, Risma K, Jordan MB. Perforin is a critical physiologic regulator of T-cell activation. Blood 2011; 118:618-26; PMID:21606480; http://dx.doi.org/10.1182/blood-2010-12-324533.
29. Boissonnas A, Scholer-Dahirel A, Simon-Blancal V, Pace L, Valet F, Kissenpfennig A, et al. Foxp3+ T cells induce perforin-dependent dendritic cell death in tumor-draining lymph nodes. Immunity 2010; 32:266- 78; PMID:20137985; http://dx.doi.org/10.1016/j.immuni.2009.11.015.
30. Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, et al. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007; 27:635-46; PMID:17919943; http://dx.doi.org/10.1016/j.immuni.2007.08.014.
31. Sad S, Kägi D, Mosmann TR. Perforin and Fas killing by CD8+ T cells limits their cytokine synthesis and proliferation. J Exp Med 1996; 184:1543- 7; PMID:8879227; http://dx.doi.org/10.1084/jem.184.4.1543.
32. Hafalla JC, Morrot A, Sano G, Milon G, Lafaille JJ, Zavala F. Early self-regulatory mechanisms control the magnitude of CD8+ T cell responses against liver stages of murine malaria. J Immunol 2003; 171:964-70; PMID:12847268.
33. Wong P, Pamer EG. Feedback regulation of pathogenspecific T cell priming. Immunity 2003; 18:499-511; PMID:12705853; http://dx.doi.org/10.1016/S1074-7613(03)00081-5.
34. Chen M, Felix K, Wang J. Critical role for perforin and Fas-dependent killing of dendritic cells in the control of inflammation. Blood 2012; 119:127-36; PMID:22042696; http://dx.doi.org/10.1182/blood-2011-06-363994.
35. Brincks EL, Katewa A, Kucaba TA, Griffith TS, Legge KL. CD8 T cells utilize TRAIL to control influenza virus infection. J Immunol 2008; 181:4918-25; PMID:18802095.
36. Zhang M, Park SM, Wang Y, Shah R, Liu N, Murmann AE, et al. Serine protease inhibitor 6 protects cytotoxic T cells from self-inflicted injury by ensuring the integrity of cytotoxic granules. Immunity 2006; 24:451-61; PMID:16618603; http://dx.doi.org/10.1016/j.immuni.2006.02.002.
37. Hudrisier D, Riond J, Mazarguil H, Gairin JE, Joly E. Cutting edge: CTLs rapidly capture membrane fragments from target cells in a TCR signalingdependent manner. J Immunol 2001; 166:3645-9; PMID:11238601.
38. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252- 64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239.
39. Matter M, Pavelic V, Pinschewer DD, Mumprecht S, Eschli B, Giroglou T, et al. Decreased tumor surveillance after adoptive T-cell therapy. Cancer Res 2007; 67:7467-76; PMID:17671217; http://dx.doi.org/10.1158/0008-5472.CAN-06-4372.
40. Lena G, Trapani JA, Sutton VR, Ciccone A, Browne KA, Smyth MJ, et al. Dihydrofuro[3,4-c]pyridinones as inhibitors of the cytolytic effects of the pore-forming glycoprotein perforin. J Med Chem 2008; 51:7614- 24; PMID:19007200; http://dx.doi.org/10.1021/jm801063n.
41. Pircher H, Bürki K, Lang R, Hengartner H, Zinkernagel RM. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 1989; 342:559-61; PMID:2573841; http://dx.doi.org/10.1038/342559a0.
42. Kägi D, Ledermann B, Bürki K, Seiler P, Odermatt B, Olsen KJ, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369:31-7; PMID:8164737; http://dx.doi.org/10.1038/369031a0.
43. Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994; 76:17- 27; PMID:8287475; http://dx.doi.org/10.1016/0092-8674(94)90169-4.
44. Barnden MJ, Allison J, Heath WR, Carbone FR. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol Cell Biol 1998; 76:34-40; PMID:9553774; http://dx.doi.org/10.1046/j.1440-1711.1998.00709.x.
45. Finnberg N, Gruber JJ, Fei P, Rudolph D, Bric A, Kim SH, et al. DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol 2005; 25:2000-13; PMID:15713653; http://dx.doi.org/10.1128/MCB.25.5.2000-2013.2005.
46. Garrigan K, Moroni-Rawson P, McMurray C, Hermans I, Abernethy N, Watson J, et al. Functional comparison of spleen dendritic cells and dendritic cells cultured in vitro from bone marrow precursors. Blood 1996; 88:3508-12; PMID:8896417.
47. Perret R, Ronchese F. Effector CD8+ T cells activated in vitro confer immediate and long-term tumor protection in vivo. Eur J Immunol 2008; 38:2886- 95; PMID:18825745; http://dx.doi.org/10.1002/eji.200838483.
48. Robinson MJ, Ronchese F, Miller JH, La Flamme AC. Paclitaxel inhibits killing by murine cytotoxic T lymphocytes in vivo but not in vitro. Immunol Cell Biol 2010; 88:291-6; PMID:19997079; http://dx.doi.org/10.1038/icb.2009.96.
49. Hermans IF, Daish A, Moroni-Rawson P, Ronchese F. Tumor-peptide-pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge. Cancer Immunol Immunother 1997; 44:341- 7; PMID:9298937; http://dx.doi.org/10.1007/s002620050392.
50. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005; 174:7516-23; PMID:15944250.